. "Appendix B: Polling Results." Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press, 2010.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary
Questions
Responses
Percentage
Count
How important do you feel precompetitive collaboration is to biomedical research?
Not at all important
5
1
Somewhat important
0
0
Important
5
1
Very important
23
5
Critical
68
15
Which research activity do you feel can benefit most from precompetitive collaboration?
Bioinformatics/software development
4
1
Data generation/collection efforts
35
8
Basic research
17
4
Translational/disease-focused research
35
8
Product-oriented research
9
2
What do you see as the biggest hurdle to precompetitive collaboration in biomedicine?
Individualist/competitive culture among academics
30
6
Proprietary culture of industry
25
5
Intellectual property issues
25
5
Academic promotion/tenure process
15
3
Publications
0
0
Patient privacy concerns
5
1
How relevant/applicable are industry collaborations, such as SEMATECH, to biomedical research?
Not at all important
0
0
Somewhat important
16
3
Important
16
3
Very important
42
8
Critical
26
5
How relevant/applicable are prizes, such as InnoCentive offers, to biomedical research?
